These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 38202077)

  • 61. Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma.
    Goparaju K; Caimi PF
    Expert Opin Biol Ther; 2021 Nov; 21(11):1373-1381. PubMed ID: 34505550
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
    Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
    Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
    Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma.
    Vijenthira A; Kuruvilla J; Crump M; Jain M; Prica A
    J Clin Oncol; 2023 Mar; 41(8):1577-1589. PubMed ID: 36315922
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
    Morschhauser F; Flinn IW; Advani R; Sehn LH; Diefenbach C; Kolibaba K; Press OW; Salles G; Tilly H; Chen AI; Assouline S; Cheson BD; Dreyling M; Hagenbeek A; Zinzani PL; Jones S; Cheng J; Lu D; Penuel E; Hirata J; Wenger M; Chu YW; Sharman J
    Lancet Haematol; 2019 May; 6(5):e254-e265. PubMed ID: 30935953
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma.
    Albanyan O; Chavez J; Munoz J
    Ther Adv Hematol; 2022; 13():20406207221141511. PubMed ID: 36505886
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Advances in Polatuzumab Vedotin-PIIQ Therapy: A Review of Treatment Efficacy in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma.
    Abdur Raqib M; Haseeb A; Shafique MA; Fadlalla Ahmed TK; Mustafa MS
    Pediatric Health Med Ther; 2023; 14():323-331. PubMed ID: 37867604
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches.
    Hernandez-Ilizaliturri FJ; Czuczman MS
    Oncology (Williston Park); 2009 May; 23(6):546-53. PubMed ID: 19544696
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL.
    Tabbara N; Gaut D; Oliai C; Lewis T; de Vos S
    Leuk Res Rep; 2021; 16():100260. PubMed ID: 34354920
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
    Tilly H; Morschhauser F; Bartlett NL; Mehta A; Salles G; Haioun C; Munoz J; Chen AI; Kolibaba K; Lu D; Yan M; Penuel E; Hirata J; Lee C; Sharman JP
    Lancet Oncol; 2019 Jul; 20(7):998-1010. PubMed ID: 31101489
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma.
    Thuresson PO; Vander Velde N; Gupta P; Talbot J
    Adv Ther; 2020 Dec; 37(12):4877-4893. PubMed ID: 33001384
    [TBL] [Abstract][Full Text] [Related]  

  • 72. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
    Abramson JS; Ghosh N; Smith SM
    Am Soc Clin Oncol Educ Book; 2020 May; 40():302-313. PubMed ID: 32421455
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.
    Nowakowski GS; Yoon DH; Peters A; Mondello P; Joffe E; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Huang D; Waltl EE; Winderlich M; Kurukulasuriya NC; Ambarkhane S; Hess G; Salles G
    Clin Cancer Res; 2022 Sep; 28(18):4003-4017. PubMed ID: 35674661
    [TBL] [Abstract][Full Text] [Related]  

  • 74. High-dose rituximab in combination with autologous stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma.
    Shi YF; Zhou SJ; Sun L; Yu K; Chen Y
    Med Clin (Barc); 2020 Sep; 155(6):235-241. PubMed ID: 32173075
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective study.
    Yagi Y; Kanemasa Y; Sasaki Y; Sei M; Matsuo T; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Morita Y; Tamura T; Nakamura S; Okuya T; Shimizuguchi T; Shingai N; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Shimoyama T
    Cancer Med; 2023 Sep; 12(17):17808-17821. PubMed ID: 37635630
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma.
    Nowakowski GS; Yoon DH; Mondello P; Joffe E; Peters A; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Sabatelli L; Waltl EE; Winderlich M; Sporchia A; Kurukulasuriya NC; Cordoba R; Hess G; Salles G
    Ann Hematol; 2023 Sep; 102(9):2643-2644. PubMed ID: 37432417
    [No Abstract]   [Full Text] [Related]  

  • 77. Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data.
    Sawalha Y; Maddocks K
    Onco Targets Ther; 2020; 13():5123-5133. PubMed ID: 32606733
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options.
    Vodicka P; Klener P; Trneny M
    Onco Targets Ther; 2022; 15():1481-1501. PubMed ID: 36510607
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tafasitamab: First Approval.
    Hoy SM
    Drugs; 2020 Nov; 80(16):1731-1737. PubMed ID: 32946059
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Dere RC; Beardsley RL; Lu D; Lu T; Ku GH; Man G; Nguyen V; Kaur S
    Front Immunol; 2023; 14():1119510. PubMed ID: 37063860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.